Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer

Trial Profile

Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NabucCO
  • Most Recent Events

    • 02 Feb 2017 Status changed from recruiting to completed.
    • 11 Oct 2016 Results of Phase I portion (n=63) of study presented at the 41st European Society for Medical Oncology Congress.
    • 15 May 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jul 2015 to 1 Dec 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top